Concord Asset Management (Virginia)’s Regeneron Pharmaceuticals REGN Stock Holding History

Concord Asset Management (Virginia)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,259	Closed	-$1.33M	–	203
2025 Q1	$1.33M	Buy	2,259 +972	+76%	+$669K	0.29%	77
2024 Q4	$917K	Buy	1,287 +223	+21%	+$187K	0.2%	85
2024 Q3	$1.12M	Buy	1,064 +152	+17%	+$169K	0.25%	71
2024 Q2	$959K	Buy	912 +388	+74%	+$376K	0.24%	80
2024 Q1	$504K	Buy	524 +48	+10%	+$45.6K	0.13%	103
2023 Q4	$418K	Buy	+476	New	+$392K	0.12%	107

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Concord Asset Management (Virginia)'s REGN Position: Q2 2025 in Review

Concord Asset Management (Virginia) sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 2,259 shares — an estimated $1.33M sold.

Concord Asset Management (Virginia) first reported a position in REGN in Q4 2023 and held it in 6 quarters. The position peaked at $1.33M in Q1 2025. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Concord Asset Management (Virginia) reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Concord Asset Management (Virginia) sold 2,259 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $1.33M.
Concord Asset Management (Virginia) first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Concord Asset Management (Virginia)'s Regeneron Pharmaceuticals position peaked at $1.33M in Q1 2025.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Concord Asset Management (Virginia)'s 13F filing for Q2 2025, filed 25 Jul 2025.